All News
Filter News
Found 808,676 articles
-
Orion Biotechnology and Peptilogics Enter Strategic Research Collaboration to Enable AI-Driven Drug Discovery Against Undrugged GPCR Target
7/12/2022
Orion Biotechnology Canada Ltd and Peptilogics, announced today that they have entered a research and development collaboration to leverage AI for drug discovery against an undrugged GPCR target.
-
Endogena Therapeutics transitions into clinical stage with its novel regenerative treatment for blindness caused by retinitis pigmentosa
7/12/2022
Endogena Therapeutics Inc. announced today that the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP).
-
B. Braun Launches Introcan Safety® 2 IV Catheter with One-time Blood Control Designed to Make IV Access Safer for Clinicians
7/12/2022
B. Braun Medical Inc. (B. Braun), a leader in infusion therapy, announced today the launch of its new Introcan Safety 2 IV Catheter with one-time blood control.
-
Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
7/12/2022
Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, announced today that enrollment has begun in a Phase 1/2a clinical trial of CYB003, the first novel psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder (“MDD”).
-
Ancora Heart Receives Breakthrough Device Designation from FDA for the AccuCinch® Ventricular Restoration System
7/12/2022
Ancora Heart Receives Breakthrough Device Designation from FDA for the AccuCinch ® Ventricular Restoration System.
-
OmniPathology Announces the Launch of its Oropharyngeal HPV PCR TestNew oropharyngeal Human Papillomavirus (HPV) PCR test helps screen for oropharyngeal cancer and detection of early premalignant lesions
7/12/2022
OmniPathology, an independent, physician-owned and operated pathology lab, today announced the launch of a new oral test for human papillomavirus (HPV) that can cause cancer.
-
Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
7/12/2022
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, has completed patient enrollment in its clinical study evaluating an “extra-strength” dose for extended duration of Jeuveau® (prabotulinumtoxinA-xvfs), its flagship neurotoxin product and the first and only neurotoxin dedicated exclusively to aesthetics.
-
Affini-T Therapeutics Appoints Jill DeSimone to its Board of Directors
7/12/2022
Affini-T Therapeutics, Inc ., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced the appointment of Jill DeSimone to its board of directors.
-
SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)
7/12/2022
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced approximately $28 million of procurement orders for oral TPOXX® (tecovirimat).
-
Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic Cardiomyopathy
7/12/2022
Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced it has expanded its pipeline to advance an AAV gene therapy program as a potential precision therapy for three genetic segments of arrhythmogenic cardiomyopathy (ACM).
-
Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS‑CoV‑2
7/12/2022
Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS ‑CoV‑2.
-
AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose
7/12/2022
AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), announced today their publication in collaboration with researchers at Arizona State University (ASU) entitled, “Third COVID-19 Vaccine Dose Boosts Neutralizing Antibodies in Poor Responders” in Communications Medicine, part of the Nature family of journals.
-
Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual Disease
7/12/2022
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, has added another patent family to its molecular residual disease (MRD)-related IP portfolio, with priority to January 2013.
-
Readout Health Biosense device to be tested in JDRF-funded clinical trial in people with Type 1 Diabetes using SGLT inhibitors at Washington University
7/12/2022
Readout Health, a medical digital health startup, announces a sponsored research agreement with Washington University School of Medicine in St. Louis that received a $360,000 research grant from JDRF.
-
Quantabio’s New qScript Ultra Product Family Builds on More Than 20 Years of RNA and DNA Enzyme Technology Innovation
7/12/2022
Quantabio , a leading provider of robust DNA and RNA amplification reagents for the most demanding molecular testing and life science research applications, today announced the commercial availability of the qScript Ultra Flex Kit and the qScript Ultra SuperMix for the synthesis of first-strand complementary DNA (cDNA).
-
Abbott Receives FDA's Breakthrough Device Designation to Explore Use of Deep Brain Stimulation to Manage Severe Depression
7/12/2022
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to investigate the use of its deep brain stimulation (DBS) system in treatment-resistant depression (TRD), a form of major depressive disorder (MDD).
-
Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)
7/12/2022
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, today announced the initiation of the CANYON Phase 2 clinical trial evaluating EDG-5506 in individuals with BMD.
-
MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs
7/12/2022
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), today announces the signing of a strategic platform license (SPL) with LG Chem Ltd., a globally diversified chemical company established in petrochemical, advanced materials and bio-technology, aiming to create new value for its customers based on science.
-
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer
7/12/2022
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that John Dillman has been appointed as the Company’s Chief Commercial Officer.
-
Y-mAbs’ Announces Clearance of IND for GD2-SADA
7/12/2022
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced initiation of its first clinical trial with a SADA construct.